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Abstract
To identify genetic variants influencing plasma lipid concentrations, we first used genotype 
imputation and meta-analysis to combine three genome-wide scans totaling 8,816 individuals and 
comprising 6,068 individuals specific to our study (1,874 individuals from the FUSION study of 
type 2 diabetes and 4,184 individuals from the SardiNIA study of aging-associated variables) and 
2,758 individuals from the Diabetes Genetics Initiative, reported in a companion study in this 
issue. We subsequently examined promising signals in 11,569 additional individuals. Overall, we 
identify strongly associated variants in eleven loci previously implicated in lipid metabolism 
(ABCA1, the APOA5-APOA4-APOC3-APOA1 and APOE-APOC clusters, APOB, CETP, 
GCKR, LDLR, LPL, LIPC, LIPG and PCSK9) and also in several newly identified loci (near 
MVK-MMAB and GALNT2, with variants primarily associated with high-density lipoprotein 
(HDL) cholesterol; near SORT1, with variants primarily associated with low-density lipoprotein 
(LDL) cholesterol; near TRIB1, MLXIPL and ANGPTL3, with variants primarily associated with 
triglycerides; and a locus encompassing several genes near NCAN, with variants strongly 
associated with both triglycerides and LDL cholesterol). Notably, the 11 independent variants 
associated with increased LDL cholesterol concentrations in our study also showed increased 
frequency in a sample of coronary artery disease cases versus controls.
Coronary artery disease (CAD) and stroke are the leading causes of morbidity, mortality and 
disability in industrialized countries, and the prevalence of these diseases is increasing 
rapidly in developing countries1. A main underlying pathology is atherosclerosis, a process 
of cumulative deposition of LDL cholesterol in the arteries supplying blood to the heart and 
brain that eventually leads to impaired or absent blood supply and myocardial infarction or 
stroke1. Consistent and compelling evidence has demonstrated association between 
lipoprotein-associated lipid concentrations and cardiovascular disease incidence 
worldwide2–4. Whereas high concentrations of LDL cholesterol are associated with 
increased risk of CAD, high concentrations of HDL cholesterol are associated with 
decreased risk of CAD. Specifically, it has been estimated that each 1% decrease in LDL 
cholesterol concentrations reduces the risk of coronary heart disease by ~1% (ref. 5), and 
each 1% increase in HDL cholesterol concentrations reduces the risk of coronary heart 
disease by ~2% (ref. 6). A recent meta-analysis of data on 150,000 individuals, including 
3,000 with CAD-related deaths, shows that the two factors are independently associated with 
CAD risk7. There is evidence that a high concentration of triglycerides is an additional, 
independent risk factor for cardiovascular disease8,9, although whether this association is 
causal is still under debate.
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Smoking, diet and physical activity all have a role in determining individual lipid profiles. 
Still, family studies suggest that in many populations, about half of the variation in these 
traits is genetically determined10,11, and it is clear that LDL cholesterol, HDL cholesterol 
and triglyceride concentrations are strongly influenced by the genetic constitution of each 
individual. Furthermore, genetic variants that increase LDL cholesterol concentrations—
such as rare variants in the LDL receptor (LDLR) and apolipoprotein B (APOB) genes and 
common variants in the apolipoprotein E (APOE) gene—have also been associated with 
increased susceptibility to coronary heart disease12. Thus, the available evidence 
demonstrates not only that genetic variants account for a substantial fraction of individual 
variation in lipid concentrations, but also that lipid concentrations are associated with the 
risk of CAD.
Although several genes and genetic variants have been found that associate with individual 
variation in lipid concentrations, additional variants influencing these traits remain to be 
identified. As with other complex traits, identification of genes influencing lipid 
concentrations is likely to be much enhanced by large sample sizes. Thus, we decided to 
combine genome-wide association scan data from two of our studies, including 1,874 
individuals from the FUSION study of type 2 diabetes13 and 4,184 individuals from the 
SardiNIA study of aging-associated variables10,14, with data on 2,758 individuals from the 
Diabetes Genetics Initiative15,16. Here, we describe results of a combined analysis of the 
three genome-wide association scans involving a total of 8,816 individuals and our follow-
up assessments of up to 11,569 individuals, which were done in order to verify common 
genetic variants associated with plasma concentrations of LDL cholesterol, HDL cholesterol 
and triglycerides. Our results identify >25 independent common variants associated with 
individual variation in lipid concentrations (each with P < 5 × 10−8). Some are located in 
previously implicated loci, indicating that our approach was valid, and others are found in 
loci where genetic variants have not been previously implicated in lipid metabolism. Our 
results also provide promising, albeit not definitive, evidence of association between several 
other common variants and lipid concentrations. In a companion manuscript, Kathiresan and 
colleagues from the Diabetes Genetics Initiative report results of their own follow-up 
genotyping of SNPs selected on the basis of our combined analysis of the three scans, their 
original analyses, and previously published reports. Their independent follow-up samples 
and genotyping further support the newly identified loci reported here.
RESULTS
Genome-wide association scans
To survey the genome for common variants associated with plasma concentrations of HDL 
cholesterol, LDL cholesterol and triglyceride concentrations, we conducted genome-wide 
association scans on two different populations. In one scan, after we excluded markers on 
the basis of quality-control filters (see Methods), we examined 304,581 SNPs with minor 
allele frequency (MAF) >1% from the Illumina HumanHap300 BeadChip and a GoldenGate 
panel designed to improve coverage around type 2 diabetes (T2D) candidate genes in 1,874 
Finnish individuals from the Finland–United States Investigation of NIDDM Genetics 
(FUSION) study13. In a second scan, after quality-control filtering, we examined 356,539 
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SNPs (MAF > 5%) from the Affymetrix 500K Mapping Array Set in 4,184 individuals from 
the SardiNIA Study of Aging10,14. The Sardinian sample is organized into a number of 
small-to medium-sized pedigrees. We took advantage of this relatedness to reduce 
genotyping costs: we genotyped 1,412 individuals with the Affymetrix 500K Mapping Array 
Set (organized into groups of 2–3 individuals per nuclear family) and then propagated their 
genotypes to the remaining individuals, who were genotyped using only the Affymetrix 10K 
Mapping Array14,17,18 (see Methods). To increase statistical power, we also contacted the 
authors of a previously published study15 to obtain results for 347,010 SNPs (MAF > 5%) 
genotyped in 2,758 Finnish and Swedish individuals from the Diabetes Genetics Initiative 
(DGI) using the Affymetrix 500K Mapping Array Set. Further details of the DGI study and 
independent follow-up analyses are provided in a companion manuscript16. All three initial 
scans excluded individuals taking lipid lowering therapies, for a total of 8,816 phenotyped 
individuals (Table 1). Informed consent was obtained from all study participants and ethics 
approval was obtained from the participating institutions.
Because the three studies used different marker sets with an overlap of only 44,998 SNPs 
across studies, we used information on patterns of haplotype variation in the HapMap CEU 
samples (release 21)19 to infer missing genotypes in silico and to facilitate comparison 
between the studies13. Imputation analyses were carried out with Markov Chain 
Haplotyping software (MaCH; see URLs section in Methods). For our analyses, we only 
considered SNPs that were either genotyped or could be imputed with relatively high 
confidence; that is, SNPs for which patterns of haplotype sharing between sampled 
individuals and those genotyped by the HapMap consistently indicated a specific allele. 
Comparison of imputed and experimentally derived genotypes in our samples yielded 
estimated error rates of 1.46% (for imputation based on Illumina genotypes) to 2.14% 
(imputation based on Affymetrix genotypes) per allele, consistent with expectations from 
HapMap data. For additional details of quality-control and imputation procedures, see 
Methods and Supplementary Table 1 online.
We then conducted a series of association analyses to relate the ~2,261,000 genotyped 
and/or imputed SNPs with plasma concentrations of HDL cholesterol, LDL cholesterol and 
triglyceride concentrations. For each SNP, lipid concentrations were regressed onto allele 
counts in a regression model that also included gender, age and age2 as covariates. For the 
FUSION sample, we analyzed T2D cases and controls separately, and added additional 
covariates accounting for birth province and study subset. For the DGI sample, we analyzed 
cases and controls together using an additional covariate to indicate diabetes status. For 
SNPs genotyped in the lab, allele counts were discrete (0, 1 or 2), whereas for SNPs 
genotyped in silico, allele counts were fractional (between 0.0 and 2.0, depending on the 
imputed number of copies of the allele for each individual; see Methods). To allow for 
relatedness in the FUSION and SardiNIA samples, we estimated regression coefficients in 
the context of a variance component model that modeled background polygenic effects17. As 
usual20,21, modeling polygenic effects is important in the context of an association study 
such as this one, because ignoring relatedness among sampled individuals can lead to 
misleading P values and inflated false-positive rates.
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Figure 1 shows the results of a meta-analysis of the initial scans from all three studies, 
comprising a total of 8,816 participants. The genomic control22 parameters for this meta-
analysis were 1.04, 1.02 and 1.01 (for HDL cholesterol, LDL cholesterol and triglycerides, 
respectively), suggesting that population stratification and unmodeled relatedness had 
negligible impact on our association results. Stage 1 results indicate strong association with 
lipids for 18 loci where at least one SNP exceeds the arbitrary threshold of P < 5 × 10−7 
(Table 2). Several loci previously implicated in lipid metabolism show strong evidence for 
association, including regions near CETP (strongest association at rs3764261, P < 10−18, 
HDL cholesterol concentration increase of 2.42 mg/dl per A allele), LPL (rs12678919, P < 
10−10, 2.44 mg/dl increase per G allele), LIPC (rs10468017, P < 10−10, 1.76 mg/dl increase 
per T allele), ABCA1 (rs4149274, P ~7.4 × 10−8, 1.51 mg/dl increase per G allele) and 
LIPG (rs4939883, P ~1.4 × 10−7, 1.87 mg/dl increase per C allele) associated with HDL 
cholesterol concentrations; the APOE-APOC1-APOC4-APOC2 cluster (rs4420638, P < 
10−20, 8.02 mg/dl increase per G allele), APOB (rs515135, P < 10−13, 6.08 mg/dl increase 
per C allele) and LDLR (rs6511720, P < 10−9, 8.03 mg/dl increase per C allele) associated 
with LDL cholesterol concentrations; and near the APOA5-APOA4-APOC3-APOA1 cluster 
(rs964184, P < 10−15, 18.12 mg/dl increase per G allele), GCKR (rs1260326, P < 10−14, 
10.25 mg/dl increase per T allele) and LPL (rs6993414, P < 10−12, 14.20 mg/dl increase per 
A allele) associated with triglyceride concentrations. At several of these loci, the SNP 
showing strongest association was in linkage disequilibrium (LD) with previously identified 
variants (r2 > 0.80) or had itself been previously reported to show association. However, at 
other loci—in particular, the regions near LIPC, LIPG, LDLR and APOB—strongly 
associated SNPs were in only weak LD with previously identified variants (r2 < 0.30) and 
thus were likely to represent new signals (Supplementary Table 2 online). At the GCKR 
locus, the strongest observed association was with a coding SNP, consistent with the results 
of a recent detailed analysis of the region (S. Kathiresan and M. Orho-Melander, personal 
communication). In addition to SNPs in these known loci, several other SNPs showed strong 
association in our initial genome-wide analysis. For example, SNPs near the GRIN3A, 
GALNT2, CELSR2-PSRC1-SORT1, NCAN-SF4 and TRIB1 genes all had P values <5 × 
10−7 for at least one of the three lipid traits in our initial analysis (Table 2). We observed 
association with distinct gene sets for each of the three traits, consistent with the modest 
degree of correlation between the traits (the correlation between HDL and LDL cholesterol 
was essentially zero in our samples, the correlation between HDL cholesterol and 
triglycerides was approximately −0.4 and the correlation between LDL cholesterol and 
triglycerides was 0.3 in the SardiNIA sample and 0.1 in FUSION).
Follow-up of initial findings
To further evaluate these and other promising findings from our initial scan, we examined a 
subset of SNPs in six additional cohorts of European ancestry, totaling 11,569 individuals 
(Table 1). These follow-up analyses were conducted in several stages. In a first round of 
follow-up analysis, SNPs included on the Affymetrix arrays (genotyped in SardiNIA and 
DGI) and imputed or genotyped in FUSION were selected for follow-up on the basis of a 
preliminary meta-analysis. We selected a total of 100 SNPs in this manner for examination 
in the ISIS23,24, HAPI25,26 and SUVIMAX27,28 samples, and 67 SNPs for examination in 
FUSION stage 2 samples. Once imputation of HapMap SNPs was completed for SardiNIA 
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and DGI samples and an additional meta-analysis carried out, we examined nine additional 
SNPs in loci not selected for initial follow-up in the FUSION stage 2 and SUVIMAX 
samples. Finally, we genotyped a single SNP in each of the 21 loci showing promising 
evidence for replication in the initial stage 2 samples in the Caerphilly29,30 and BWHHS31 
samples (Supplementary Fig. 1 and Supplementary Methods online).
Table 3 provides a summary of the stage 2 results and a combined analysis of the data from 
both stage 1 and stage 2. The table includes the SNP with the strongest association signal at 
each locus and a selection of additional SNPs that also show strong association but only 
weak LD with the most strongly associated SNP (r2 < 0.30). All loci with a P value <5 × 
10−7 in our initial analysis were confirmed except for the association signal near GRIN3A. 
Supplementary Table 3 online provides stage 2 results for all SNPs, and Supplementary 
Table 4 online provides more detailed results for the SNPs highlighted in Table 3.
Overall, we observed the strongest evidence for association (P < 10−20) between HDL 
cholesterol and SNPs in CETP (rs3764261, rs1864163 and rs9989419; the three are in weak 
LD with each other), LIPC (rs4775041) and LPL (rs10503669); between LDL cholesterol 
and SNPs in the APOE-APOC cluster (rs4420638), near the CELSR2-PSRC1-SORT1 
(rs599839), LDLR (rs6511720) and APOB (rs562338) genes; and between triglycerides and 
SNPs near the GCKR (rs780094), APOA5-APOA4-APOC3-APOA1 (rs12286037) and LPL 
(rs10503669) genes (P values and effect sizes are shown in Table 3). In each case, we 
observed strong evidence for association in both stages of genotyping (P < 5 × 10−7). The 
association of LDL cholesterol concentrations with the CELSR2-PSRC1-SORT1 locus is 
particularly notable, because variants in the region have not been previously implicated in 
lipid metabolism (Supplementary Fig. 2c online). There is no obvious connection between 
the genes closest to the association signal, CELSR2 and PSRC1, and lipid metabolism. One 
possibility is that rs599839 or an associated variant influences expression of SORT1, a 
nearby gene that mediates endocytosis and degradation of lipoprotein lipase32. In our 
sample, allele A at rs599839 was associated with an increase of 5.48 mg/dl in LDL 
cholesterol concentrations. Notably, the same rs599839 allele has recently been associated 
with an increased risk of CAD in an independent study33, suggesting that the association to 
CAD risk might be mediated by the effect on LDL cholesterol concentrations.
Another tier of loci also remains significant after adjustment for 1,000,000 independent 
tests. This tier includes additional SNPs for loci within the previous tier and also SNPs near 
ABCA1, LIPC, LIPG and PCSK9 (Table 3). Of note, although polymorphisms in all of these 
genes have a well-established role in lipid metabolism, some of the signals we identified do 
not overlap with established associations and likely point to new risk alleles (Supplementary 
Table 2). For example, in PCSK9, variants previously associated with LDL cholesterol 
concentrations have r2 < 0.10 with the variants identified here (Supplementary Table 2). 
Other examples of newly identified risk alleles include LIPG (rs2156552), LIPC 
(rs4775041) and LDLR (rs6511720).
This tier also includes six loci where genetic variants have not previously been implicated in 
lipid metabolism. We found association between HDL cholesterol and SNPs near GALNT2 
and near MVK and MMAB (Supplementary Fig. 2a,b); between LDL cholesterol and 
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triglycerides and SNPs in an extended region near NCAN and CILP2 (Supplementary Fig. 
2d,h); and between triglycerides and SNPs near TRIB1, MLXIPL and ANGPTL3 
(Supplementary Fig. 2e–g). Among genes in these six regions, we observed the clearest 
connections to cholesterol and lipoprotein metabolism for MLXIPL, which encodes a 
protein that binds and activates specific motifs in the promoters of triglyceride synthesis 
genes, and for ANGPTL3, whose protein homolog is a major regulator of lipid metabolism 
in mice34. Rare variants in a related gene, ANGPTL4, have been associated with HDL and 
triglyceride concentrations in humans35. A connection to lipid metabolism has also been 
observed for MVK and MMAB, two neighboring genes that are regulated by SREBP2 and 
that share a common promoter36. MVK encodes mevalonate kinase, which catalyzes an 
early step in cholesterol biosynthesis, and MMAB encodes a protein that participates in a 
metabolic pathway that degrades cholesterol.
In the other three loci, we did not find any established connections to cholesterol 
metabolism. The signals near GALNT2 and TRIB1 each overlap a single gene. GALNT2 
encodes a widely expressed glycosyltransferase that could potentially modify a lipoprotein 
or receptor. TRIB1 encodes a G-protein–coupled receptor-induced protein involved in the 
regulation of mitogen-activated protein kinases37 and may regulate lipid metabolism through 
this pathway. In contrast, the association signal near NCAN extends for over 500 kb and 
encompasses 20 genes. In our combined data, rs16996148 (an Affymetrix array SNP near 
CILP2) was selected for follow-up and showed strong association with both LDL cholesterol 
(P ~ 2.7 × 10−9) and triglycerides (P ~ 2.5 × 10−9). The allele that is associated with 
increased LDL cholesterol concentrations is also associated with increased triglyceride 
concentrations, consistent with the modest positive correlation between the two traits but in 
contrast to other SNPs associated with both LDL cholesterol and triglycerides that showed 
association with only one of the traits in our sample. Notably, in the analysis of our three 
genome-wide association scans and imputed HapMap SNPs, a nonsynonymous coding SNP 
in the NCAN gene (rs2228603, Pro92Ser) showed the strongest evidence for association (P 
~ 1.8 ×10−7). This SNP was not included in our initial follow-up analysis, which considered 
only SNPs on the Affymetrix arrays, but it was in strong LD with rs16996148 (r2 = 0.89). 
NCAN is a nervous system-specific proteoglycan involved in neuronal pattern formation, 
remodeling of neuronal networks and regulation of synaptic plasticity38, with no obvious 
relation to LDL cholesterol or triglyceride concentrations.
A final tier of genes has one or more SNPs with a P value <10−5 when stage 1 and stage 2 
data are considered together (Table 3). Among these genes is LCAT, which encodes a 
protein with a well-established role in lipid metabolism, and for which well-characterized, 
but rare, genetic variants have been shown to considerably affect lipid concentrations39. Our 
signal supports a single unconfirmed report of a common variant influencing HDL 
concentrations40. Two other association signals of note are located near the B3GALT4 and 
B4GALT4 genes. Similarly to GALNT2, these genes encode glycosyltransferases, and thus 
our results may implicate glycosyltransferases as having a previously unrecognized 
influence on variation in lipid concentrations: it is possible that they affect lipid 
concentrations by modifying lipoprotein receptors41.
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A summary of evidence for association between HDL cholesterol, LDL cholesterol and 
triglycerides and all markers genotyped or imputed in our initial survey of the genome is 
available online (see URLs section in Methods). This should enable other investigators to 
combine our results with their own data or to select SNPs for followup in other samples. As 
an example of the utility of this resource, in a companion report, Kathiresan and 
colleagues16 used the DGI data and the meta-analysis resource to select a set of SNPs for 
examination in a sample of >18,000 individuals. They report convincing statistical evidence 
for six newly identified loci at P < 5 × 10−8, all of which overlap with those in our study.
Association with coronary artery disease
In view of the well-established associations between lipid concentrations and CAD, we 
examined whether the alleles associated with lipid concentrations in the present study were 
also associated with CAD in the Wellcome Trust Case Control Consortium (WTCCC) 
sample of ~2,000 CAD cases and an expanded reference panel of ~13,000 British 
individuals42 (including ~3,000 random controls and ~2,000 cases for each of five common 
diseases). Given the relatively modest changes in LDL cholesterol concentrations associated 
with the alleles we identified (changes of ~2–9 mg/dl per allele), we expected that a subset 
of SNPs might also be associated with a small increase in susceptibility to CAD. Notably, 
the results show that all of the alleles that were associated with increased LDL cholesterol 
concentrations in our sample were more common among CAD cases than in the expanded 
reference panel (Table 4). Among eleven independent alleles (r2 < 0.30 between nearby 
alleles) associated with increased LDL cholesterol concentrations in our sample (all with P < 
10−6 in our sample), all eleven showed increased frequency among CAD cases (P = 2−11 = 
0.0005). The increase was significant (P < 0.05) for eight of the SNPs, and nearly so (P < 
0.06) for another two (Table 4, penultimate column). Although the associated risk estimates 
are small (relative risk increases of 1.04–1.29 per allele, see Table 4), it is extremely unlikely 
(P < 10−11) that 10 of the 11 SNPs would show suggestive association with CAD at P < 0.06 
by chance, making the connection between LDL and associated SNPs and CAD particularly 
worthy of note. Overall, although we observed a correlation between the strength of the 
observed association with CAD and the impact of each allele on LDL cholesterol 
concentrations (Spearman correlation coefficient r = 0.71, P = 0.015), we also found some 
alleles that had a strong association with LDL cholesterol but no significant association with 
CAD (for example, rs562338 in the APOB locus). We did not find a similar pattern of 
association for alleles associated with the other lipid traits (Supplementary Table 5 online), 
although alleles associated with increased triglyceride concentrations near TRIB1 (for 
example, at rs17321515) were also associated with increased risk of CAD (P = 0.0008). 
Although the data suggest that nearly all alleles associated with increased LDL cholesterol 
concentrations will be associated with increased risk of CAD (given a large sample size), the 
converse is not true, as expected. Alleles at the chromosome 9 locus that show strong 
association with CAD, coronary heart disease and myocardial infarction33,42–44 do not seem 
to influence lipid concentrations in our sample (P = 0.31 for association between LDL 
cholesterol and the SNP most strongly associated with CAD, rs1333049, in our stage 1, and 
P > 0.50 for HDL cholesterol and triglycerides). Additional studies will show whether these 
variants are also associated with longevity45, stroke46 and the other health outcomes 
associated with LDL cholesterol concentrations.
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Genes at the loci implicated in our study affect the entire cycle of formation, activity and 
turnover of lipoproteins and triglycerides. Thus, they encode many of the apolipoproteins 
themselves (APOE, APOB and APOA5), but they also encode a transcription factor 
activating triglyceride synthesis (MLXIPL), an enzyme involved in cholesterol biosynthesis 
(MVK), transporters of cholesterol (ABCA1) and cholesterol ester (CETP), a lipoprotein 
receptor (LDLR), potential receptor-modifying glycosyltransferases (B4GALT4, B3GALT4 
and GALNT2), lipases (LPL, LIPC and LIPG) and a protein involved in cholesterol 
degradation (MMAB), an inhibitor of lipase (ANGPTL3) and a possible endocytic receptor 
for LPL (SORT1). Notably, some of the loci we identify (near TRIB1 and in the large region 
surrounding NCAN, for example) include no obvious functional candidates, and further 
studies to pinpoint the genes and mechanisms involved could lead to important new insights 
about lipid metabolism.
In multiple regression models, the variants identified here together accounted for only about 
5–8% of the variation in the three lipid traits in the populations studied, leaving much of the 
heritability of these traits unexplained. The missing genetic factors might be accounted for 
by a much longer list of loci with common variants of small effect, by rare variants of large 
effect that have been missed by the association approach, or by interactions between these 
and other genetic and environmental factors. To clarify the overall role of the loci reported 
here, it will be critical to resequence the exons and conserved regions in a large number of 
individuals, in order to identify and evaluate all potential variants within each gene or cluster 
of genes. This resequencing effort will help identify the functional variants involved in each 
region. In addition, resequencing may identify nonsense, nonsynonymous or other changes 
that are associated with variability in lipid concentrations, clarifying the identity of the genes 
involved in regions with multiple candidates. Resequencing of certain candidate genes has 
shown that such rare variants can sometimes be identified in individuals at the extremes of 
lipid concentration distributions47; thus, focused studies of the regions identified here in 
individuals with dyslipidaemia could be particularly informative.
Several of the loci newly identified in this report are potentially attractive drug targets. 
Furthermore, the ability to stratify individuals on the basis of specific genetic profiles may 
provide future benefits for optimization of therapy, given that lipid lowering drugs are 
already widely prescribed to help manage individual lipid profiles and reduce the risk of 
cardiovascular events2. For monogenic forms of diseases that lead to dysregulation of HDL 
cholesterol, LDL cholesterol or triglyceride concentrations, it is clear that individuals with 
different mutations require different therapeutic regimens48,49. Thus, it is our hope that 
common variants at the loci identified here will lead to development of novel therapeutics 
and influence optimal treatment profiles for each individual, resulting in improved 
management of blood lipid concentrations and reduction of cardiovascular disease risk.
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We used standard protocols to genotype the Illumina 317K HumanHap 300 BeadChip and 
Affymetrix 500K and 10K Mapping Array Sets in the FUSION and SardiNIA samples, 
respectively. We collaborated with the authors of a previously published study15 to integrate 
their results into our analysis. To facilitate comparison of results among the three studies, 
and to better assess the effects of unmeasured variants, we first identified stretches of 
haplotype shared between individuals in our sample and those in the HapMap CEU sample 
and then used these shared stretches to impute missing genotypes. This resulted in a total of 
~2,261,000 SNPs that were either genotyped or imputed with high confidence in all three 
samples.
Association analysis
We first analyzed each study independently. For each marker, we identified a reference allele 
and calculated statistics summarizing its evidence for association with HDL cholesterol, 
LDL cholesterol and triglycerides. Association models include gender, age and age2 as 
covariates, and additional covariates appropriate to each study. These statistics were then 
combined across studies taking into account both the number of phenotyped individuals in 
each study and the direction and magnitude of the estimated effect.
Follow-up
SNPs from the loci showing the strongest evidence for association in the genome-wide scans 
were selected for analysis in follow-up samples. In our initial round of follow-up, we 
favored SNPs that were successfully genotyped in both the DGI and SardiNIA studies. As in 
the analysis of the initial scans, we first conducted analyses within each sample separately 
and then combined the resulting summary statistics by meta-analysis.
Coronary artery disease analysis
Individual genotype data for this analysis were obtained from the WTCCC website. We first 
imputed all relevant untyped SNPs using the HapMap CEU as a reference population and 
carried out tests for association with a likelihood-ratio test.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
We are indebted to the many volunteers who generously participated in these studies. We thank our colleagues from 
the DGI for sharing prepublication data; M. Erdos, P. Chines, P. Deodhar, K. Kubalanza, A. Sprau and M. Tong of 
FUSION and E. Pugh, K. Doheny and Center for Inherited Disease Research (CIDR) investigators for expert 
technical work; N. Rosenberg for helpful discussions about population genetics; the SardiNIA Research Clinic 
staff; and the Amish Research Clinic staff. This study makes use of data generated by the Wellcome Trust Case 
Control Consortium. A full list of the investigators who contributed to the generation of the data are available from 
the WTCCC website. Funding for the WTCCC project was provided by the Wellcome Trust under award 076113. 
The Caerphilly study was funded by the Medical Research Council (UK). The Caerphilly study was undertaken by 
the former MRC Epidemiology Unit (South Wales) and was funded by the Medical Research Council of the United 
Willer et al. Page 10













Kingdom. The data archive is maintained by the Department of Social Medicine, University of Bristol. This work 
was supported in part by the Intramural Research Program of the National Institute on Aging (NIA), by extramural 
grants from National Human Genome Research Institute (NHGRI), the National Diabetes and Digestive and Kidney 
Diseases (NIDDK) and the National Heart Lung and Blood Institute (NHLBI), by the American Diabetes 
Association, the Department of Veterans Affairs, the British Heart Foundation, the Medical Research Council of the 
United Kingdom and the French Ministry of Higher Education and Research. FUSION genome-wide genotyping 
was carried out by the Johns Hopkins University Genetic Resources Core Facility (GRCF) SNP Center at CIDR 
with support from CIDR NIH (contract N01-HG-65403) and the GRCF SNP Center. Additional support for the 
SardiNIA study was provided by the mayors, administration and residents of Lanusei, Ilbono, Arzana and Elini and 
the head of Public Health Unit ASL4 in Sardinia. C.J.W. is the recipient of a postdoctoral fellowship from the 
American Diabetes Association. G.R.A. and K.L.M. are Pew Scholars for the Biomedical Sciences.
References
1. Mackay, J.; Mensah, GA. The Atlas of Heart Disease and Stroke. World Health Organization; 
Geneva: 2004. 
2. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein 
cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. Br Med J. 
2003; 326:1423. [PubMed: 12829554] 
3. Kuulasmaa K, et al. Estimation of contribution of changes in classic risk factors to trends in 
coronary-event rates across the WHO MONICA Project populations. Lancet. 2000; 355:675–687. 
[PubMed: 10703799] 
4. Clarke R, et al. Cholesterol fractions and apolipoproteins as risk factors for heart disease mortality 
in older men. Arch Intern Med. 2007; 167:1373–1378. [PubMed: 17620530] 
5. Grundy SM, et al. Implications of recent clinical trials for the National Cholesterol Education 
Program Adult Treatment Panel III guidelines. Circulation. 2004; 110:227–239. [PubMed: 
15249516] 
6. Gotto AM Jr, Brinton EA. Assessing low levels of high-density lipoprotein cholesterol as a risk 
factor in coronary heart disease: a working group report and update. J Am Coll Cardiol. 2004; 
43:717–724. [PubMed: 14998606] 
7. Prospective Studies Collaboration. Blood cholesterol and vascular mortality by age, sex and blood 
pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular 
deaths. Lancet. 2007; 370:1829–1839. [PubMed: 18061058] 
8. Bansal S, et al. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in 
women. J Am Med Assoc. 2007; 298:309–316.
9. Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of 
myocardial infarction, ischemic heart disease, and death in men and women. J Am Med Assoc. 
2007; 298:299–308.
10. Pilia G, et al. Heritability of cardiovascular and personality traits in 6,148 Sardinians. PLoS Genet. 
2006; 2:e132. [PubMed: 16934002] 
11. Pollin TI, et al. A genome-wide scan of serum lipid levels in the Old Order Amish. 
Atherosclerosis. 2004; 173:89–96. [PubMed: 15177127] 
12. Breslow JL. Genetics of lipoprotein abnormalities associated with coronary artery disease 
susceptibility. Annu Rev Genet. 2000; 34:233–254. [PubMed: 11092828] 
13. Scott LJ, et al. A genome-wide association study of type 2 diabetes in Finns detects multiple 
susceptibility variants. Science. 2007; 316:1341–1345. [PubMed: 17463248] 
14. Scuteri A, et al. Genome-wide association scan shows genetic variants in the FTO gene are 
associated with obesity related traits. PLoS Genet. 2007; 3:e115. [PubMed: 17658951] 
15. Saxena R, et al. Genome-wide association analysis identifies loci for type 2 diabetes and 
triglyceride levels. Science. 2007; 316:1331–1336. [PubMed: 17463246] 
16. Kathiresan S, et al. Six new loci associated with blood low-density lipoprotein cholesterol, high-
density lipoprotein cholesterol or triglycerides in humans. Nat Genet. advance online publication 
13 January 2008. 
17. Chen WM, Abecasis GR. Family-based association tests for genome-wide association scans. Am J 
Hum Genet. 2007; 81:913–926. [PubMed: 17924335] 
Willer et al. Page 11













18. Burdick JT, Chen WM, Abecasis GR, Cheung VG. In silico method for inferring genotypes in 
pedigrees. Nat Genet. 2006; 38:1002–1004. [PubMed: 16921375] 
19. The International HapMap Consortium. The International HapMap Project. Nature. 2005; 
437:1299–1320. [PubMed: 16255080] 
20. George VT, Elston RC. Testing of association between polymorphic markers and quantitative traits 
in pedigrees. Genet Epidemiol. 1987; 4:193–201. [PubMed: 3609719] 
21. Abecasis GR, Cardon LR, Cookson WOC. A general test of association for quantitative traits in 
nuclear families. Am J Hum Genet. 2000; 66:279–292. [PubMed: 10631157] 
22. Devlin B, Roeder K. Genomic control for association studies. Biometrics. 1999; 55:997–1004. 
[PubMed: 11315092] 
23. ISIS-3 Collaborative Group. ISIS-3: a randomised comparison of streptokinase vs tissue 
plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 
cases of suspected acute myocardial infarction. ISIS-3 (Third International Study of Infarct 
Survival) Collaborative Group. Lancet. 1992; 339:753–770. [PubMed: 1347801] 
24. Keavney B, et al. Lipid-related genes and myocardial infarction in 4685 cases and 3460 controls: 
discrepancies between genotype, blood lipid concentrations, and coronary disease risk. Int J 
Epidemiol. 2004; 33:1002–1013. [PubMed: 15256516] 
25. Post W, et al. Associations between genetic variants in the NOS1AP (CAPON) gene and cardiac 
repolarization in the old order Amish. Hum Hered. 2007; 64:214–219. [PubMed: 17565224] 
26. Post W, et al. Determinants of coronary artery and aortic calcification in the Old Order Amish. 
Circulation. 2007; 115:717–724. [PubMed: 17261661] 
27. Hercberg S, et al. The SU.VI.MAX Study: a randomized, placebo-controlled trial of the health 
effects of antioxidant vitamins and minerals. Arch Intern Med. 2004; 164:2335–2342. [PubMed: 
15557412] 
28. Hercberg S, et al. A primary prevention trial using nutritional doses of antioxidant vitamins and 
minerals in cardiovascular diseases and cancers in a general population: the SU.VI.MAX study–
design, methods, and participant characteristics. SUpplementation en VItamines et Mineraux 
AntioXydants. Control Clin Trials. 1998; 19:336–351. [PubMed: 9683310] 
29. The Caerphilly and Speedwell Collaborative Group. Caerphilly and Speedwell collaborative heart 
disease studies. J Epidemiol Community Health. 1984; 38:259–262. [PubMed: 6332166] 
30. Bainton D, et al. Plasma triglyceride and high density lipoprotein cholesterol as predictors of 
ischaemic heart disease in British men. The Caerphilly and Speedwell Collaborative Heart Disease 
Studies. Br Heart J. 1992; 68:60–66. [PubMed: 1355351] 
31. Lawlor DA, Bedford C, Taylor M, Ebrahim S. Geographical variation in cardiovascular disease, 
risk factors, and their control in older women: British Women’s Heart and Health Study. J 
Epidemiol Community Health. 2003; 57:134–140. [PubMed: 12540690] 
32. Nielsen MS, Jacobsen C, Olivecrona G, Gliemann J, Petersen CM. Sortilin/neurotensin receptor-3 
binds and mediates degradation of lipoprotein lipase. J Biol Chem. 1999; 274:8832–8836. 
[PubMed: 10085125] 
33. Samani NJ, et al. Genomewide association analysis of coronary artery disease. N Engl J Med. 
2007; 357:443–453. [PubMed: 17634449] 
34. Koishi R, et al. Angptl3 regulates lipid metabolism in mice. Nat Genet. 2002; 30:151–157. 
[PubMed: 11788823] 
35. Romeo S, et al. Population-based resequencing of ANGPTL4 uncovers variations that reduce 
triglycerides and increase HDL. Nat Genet. 2007; 39:513–516. [PubMed: 17322881] 
36. Murphy C, Murray AM, Meaney S, Gafvels M. Regulation by SREBP-2 defines a potential link 
between isoprenoid and adenosylcobalamin metabolism. Biochem Biophys Res Commun. 2007; 
355:359–364. [PubMed: 17300749] 
37. Kiss-Toth E, et al. Human tribbles, a protein family controlling mitogen-activated protein kinase 
cascades. J Biol Chem. 2004; 279:42703–42708. [PubMed: 15299019] 
38. Rauch U, Feng K, Zhou XH. Neurocan: a brain chondroitin sulfate proteoglycan. Cell Mol Life 
Sci. 2001; 58:1842–1856. [PubMed: 11766883] 
39. Kuivenhoven JA, et al. The molecular pathology of lecithin:cholesterol acyltransferase (LCAT) 
deficiency syndromes. J Lipid Res. 1997; 38:191–205. [PubMed: 9162740] 
Willer et al. Page 12













40. Pare G, et al. Genetic analysis of 103 candidate genes for coronary artery disease and associated 
phenotypes in a founder population reveals a new association between endothelin-1 and high-
density lipoprotein cholesterol. Am J Hum Genet. 2007; 80:673–682. [PubMed: 17357073] 
41. Magrane J, Casaroli-Marano RP, Reina M, Gafvels M, Vilaro S. The role of O-linked sugars in 
determining the very low density lipoprotein receptor stability or release from the cell. FEBS Lett. 
1999; 451:56–62. [PubMed: 10356983] 
42. The Welcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of 
seven common diseases and 3,000 shared controls. Nature. 2007; 447:661–678. [PubMed: 
17554300] 
43. Helgadottir A, et al. A common variant on chromosome 9p21 affects the risk of myocardial 
infarction. Science. 2007; 316:1491–1493. [PubMed: 17478679] 
44. McPherson R, et al. A common allele on chromosome 9 associated with coronary heart disease. 
Science. 2007; 316:1488–1491. [PubMed: 17478681] 
45. Barzilai N, et al. Unique lipoprotein phenotype and genotype associated with exceptional 
longevity. J Am Med Assoc. 2003; 290:2030–2040.
46. Baigent C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis 
of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005; 366:1267–1278. 
[PubMed: 16214597] 
47. Cohen JC, et al. Multiple rare alleles contribute to low plasma levels of HDL cholesterol. Science. 
2004; 305:869–872. [PubMed: 15297675] 
48. Naoumova RP, et al. Severe hypercholesterolemia in four British families with the D374Y mutation 
in the PCSK9 gene: long-term follow-up and treatment response. Arterioscler Thromb Vasc Biol. 
2005; 25:2654–2660. [PubMed: 16224054] 
49. Lind S, et al. Autosomal recessive hypercholesterolaemia: normalization of plasma LDL 
cholesterol by ezetimibe in combination with statin treatment. J Intern Med. 2004; 256:406–412. 
[PubMed: 15485476] 
Willer et al. Page 13














Summary of genome-wide association scans. The figure summarizes combined genome-
wide association scan results in the top 3 panels (plotted as −log10 P value for HDL 
cholesterol, LDL cholesterol and triglycerides). Loci that were not followed up are in gray. 
Loci that were followed-up are in green (combined dataset yielded convincing evidence of 
association, P < 5 × 10−8), orange (combined dataset yielded promising evidence of 
association, P < 10−5), or red (combined dataset did not suggest association, P > 10−5). The 
three panels in the bottom row display quantile-quantile plots for test statistics. The red line 
corresponds to all test statistics, the blue line corresponds to results after excluding statistics 
at replicated loci (in green, top panel), and the gray area corresponds to the 90% confidence 
region from a null distribution of P values (generated from 100 simulations).
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